van der Hiel B, Pauwels E K, Stokkel M P
Leiden University Medical Centre, Department of Radiology, Division of Nuclear Medicine, P.O. Box 9600, 2300 Leiden, The Netherlands.
J Cancer Res Clin Oncol. 2001 May;127(5):269-77. doi: 10.1007/s004320000191.
Positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) is considered to be a very useful adjunct to anatomic imaging techniques and is now primarily used for oncological indications. These indications include diagnosis, staging, and therapy monitoring. In this review, we discuss the articles in which FDG-PET is clinically used for monitoring therapy in breast cancer, lymphomas and gliomas. It is found that the amount of FDG uptake strongly correlates with response to therapy in breast cancer, lymphomas, and gliomas; a decrease in FDG uptake after therapy indicates a positive response to therapy. However, this conclusion is based on small patient numbers, whereas the exact response mechanism is still unknown. Therefore, more studies in comparable patient groups are required to achieve a better understanding of FDG uptake patterns after therapy. Part IIIb deals with lung, and head and neck cancer, hepatocellular and colorectal tumours, and sarcoma.
使用18F-氟脱氧葡萄糖（FDG）的正电子发射断层扫描（PET）被认为是解剖成像技术非常有用的辅助手段，目前主要用于肿瘤学适应症。这些适应症包括诊断、分期和治疗监测。在本综述中，我们讨论了FDG-PET在乳腺癌、淋巴瘤和神经胶质瘤治疗监测中的临床应用文章。研究发现，FDG摄取量与乳腺癌、淋巴瘤和神经胶质瘤的治疗反应密切相关；治疗后FDG摄取量的降低表明对治疗有阳性反应。然而，这一结论基于少量患者，而确切的反应机制仍不清楚。因此，需要在可比患者群体中进行更多研究，以更好地了解治疗后FDG摄取模式。第三部分b涉及肺癌、头颈癌、肝细胞和结肠直肠肿瘤以及肉瘤。
